Results 191 to 200 of about 89,228 (352)

Allergic Rhinitis and Its Impact on Asthma (ARIA)‐EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

open access: yesAllergy, EarlyView.
ABSTRACT Background Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI‐endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024 ...
Bernardo Sousa‐Pinto   +252 more
wiley   +1 more source

Rethinking neutrophils and eosinophils in chronic rhinosinusitis.

open access: yesJournal of Allergy and Clinical Immunology, 2021
Tim Delemarre   +3 more
semanticscholar   +1 more source

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps

open access: yesAllergy, EarlyView.
This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients.
P. E. Vonk   +13 more
wiley   +1 more source

Predictive value of tissue eosinophilia for dupilumab response in chronic rhinosinusitis with nasal polyps: A retrospective monocentric study [PDF]

open access: gold
Gian Marco Pace   +14 more
openalex   +1 more source

Long‐Term Effect of Allergen Immunotherapy in Responder Local Allergic Rhinitis Patients: Symptom Control, and Prevention of Asthma and Allergic Sensitizations

open access: yesAllergy, EarlyView.
LAR patients who respond to AIT during the first year and are treated for two more years continue improving (less symptoms and medication intake) during the following seven years. AIT prevents the onset of asthma and allergic sensitizations in responder LAR individuals during the seven years following discontinuation.
Almudena Testera‐Montes   +9 more
wiley   +1 more source

Importance of Smell Loss to Patients With Chronic Rhinosinusitis With Nasal Polyps: Options for Management and Recovery [PDF]

open access: yesClin Transl Allergy
ABSTRACT Primary diffuse type 2‐dominant chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nasal cavity and paranasal sinuses associated with significant morbidity. Impaired sense of smell is a cardinal symptom of CRSwNP and one of the most burdensome for patients, impacting quality of life, mental health, and even ...
Higgins T   +9 more
europepmc   +2 more sources

Biologics for chronic rhinosinusitis with nasal polyps.

open access: yesJournal of Allergy and Clinical Immunology, 2020
C. Bachert   +5 more
semanticscholar   +1 more source

New Allergens Approved by the WHO/IUIS Allergen Nomenclature Sub‐Committee in 2021–2024 and Their Significance for Future Diagnostics, Regulation, and Research. An EAACI Task Force Report

open access: yesAllergy, EarlyView.
ABSTRACT The WHO/IUIS Allergen Nomenclature Sub‐Committee is an international body of experts that maintains the systematic nomenclature of allergenic proteins by assigning official names to newly identified allergens submitted by researchers. Here, we summarize the data on new allergens approved between 2021 and 2024.
Christian Radauer   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy